Shani Cohen

Dynamic director with a strong background in research and development within the fields of tissue engineering and regenerative medicine. Proven track record in managing R&D projects, leading cross-functional teams, and developing innovative solutions in biotech. Skilled in project management, product development, and patent applications with a solid foundation in both theoretical and practical aspects of biomedical research and regulatory pathways into FDA approval.

• Technion, Israel Institute of Technology, Haifa, Israel, Ph.D. Researcher, Prof. Dror Selikter, 2016, 2021, Developed PEG-fibrinogen hydrogel-controlled release system for Antisense Nucleotide targeting Duchenne Muscular Dystrophy., Gene and drug delivery, biomaterials, polymers, tissue engineering.
• Ben-Gurion University of the Negev, Beer Sheva, Israel, M.Sc. Researcher, Prof. Joseph Kost, 2014, 2016, Investigated SP-D loaded PLGA nanoparticles as a drug delivery system for premature infant lung diseases., Collaboration with Cincinnati Children's Medical Center.

• Attias Cohen, S., et al., 2020, Injectable hydrogel microspheres for sustained gene delivery of Antisense Oligonucleotides to Restore the Expression of Dystrophin Protein in Duchenne Muscular Dystrophy., Journal of Controlled Release, submitted
• Attias Cohen, S., et al., 2020, SP-D loaded PLGA nanoparticles as drug delivery system for prevention and treatment of premature infant’s lung diseases., International Journal of Pharmaceutics, 585, 119387
• Kost, J., Traitel, T., Goldbart, R., Attias, S., 2018, A controlled release system for pulmonary delivery of surfactant protein D., US Patent: US 10,682,396 B2